Free Trial

Connor Clark & Lunn Investment Management Ltd. Purchases 3,573 Shares of United Therapeutics Co. (NASDAQ:UTHR)

United Therapeutics logo with Medical background
Remove Ads

Connor Clark & Lunn Investment Management Ltd. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,532 shares of the biotechnology company's stock after buying an additional 3,573 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in United Therapeutics were worth $5,127,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. MassMutual Private Wealth & Trust FSB raised its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp raised its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $131,000. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $388.25.

Remove Ads

Get Our Latest Research Report on United Therapeutics

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 116,464 shares of company stock worth $42,396,244. Company insiders own 11.90% of the company's stock.

United Therapeutics Price Performance

United Therapeutics stock traded down $5.15 during midday trading on Tuesday, reaching $317.79. 201,674 shares of the company traded hands, compared to its average volume of 442,994. The firm has a market capitalization of $14.27 billion, a price-to-earnings ratio of 13.95, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The business has a 50 day moving average of $349.12 and a two-hundred day moving average of $358.27. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 earnings per share. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads